TENS PEMF therapy in the management of Cancer
The following studies represent some of the clinical evidence for the use of TENS PEMF therapy in the management of Cancer.
Please note that these studies were not done on the Rife PEMF device, but rather represent studies including outputs which can be found on the various Rife Model MA devices.
|ELF Magnetic field induce tumor growth inhibition and apoptosis||Significant tumor growth inhibition – up to 50%. No effect on normal healthy cells.||ELF at 50Hz for four weeks.|
|Growth of injected melanoma cells is suppressed by whole body exposure to specific spatial-temporal configurations of weak intensity magnetic fields||Mice exposed to the field that was rotated through the three spatial dimensions and through all three planes every 2 sec did not grow tumors after 38 days. However, the mice in the sham-field and reference controls showed massive tumors after 38 days. Tumor growth was also affected by the intensity of the field, with mice exposed to a weak intensity field (1-5 nT) forming smaller tumors than mice exposed to sham or stronger, high intensity (2-5 microT) fields.|
|Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields||Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows
evidence of antitumor effects in patients with advanced HCC.
|410 – 642Hz very low AM ELF|
|Low Intensity and Frequency Pulsed Electromagnetic
Fields Selectively Impair Breast Cancer Cell Viability
|We observed a discrete window of vulnerability of MCF7 cells to PEMFs of 20 Hz frequency, 3 mT magnitude and
exposure duration of 60 minutes per day. The cell damage accrued in response to PEMFs increased with time and gained
significance after three days of consecutive daily exposure. By contrast, the PEMFs parameters determined to be most
cytotoxic to breast cancer MCF-7 cells were not damaging to normal MCF-10 cells.
|20Hz 3mT daily for 60 minutes a day|
|Mechanisms and therapeutic effectiveness of pulsed
electromagnetic field therapy in oncology
| In vitro studies support antineoplastic and antiangiogenic
effects of PEMF therapy. Several mechanisms of PEMF
therapy have been elucidated. For example, PEMFs inhibit
cancer growth by disrupting the mitotic spindle in a process
mediated by interference of spindle tubulin orientation
and induction of dielectrophoresis. Furthermore, PEMF
therapy modulates gene expression and protein synthesis interacting with specific DNA sequences within gene promoter
regions [18, 38, 40, 41, 58, 103]. In addition, PEMFs
inhibit angiogenesis in tumor tissues, suppressing tumor
vascularization and reducing tumor growth, as shown by
in vivo studies [95-99, 104].
The specific claim, supported by the described in vivo
studies, is that all treated groups showed slower tumor
growth rate if compared with untreated control group,
confirming that PEMF therapy can modulate the physiology
and electrochemistry of cancer cells and influence
cell membrane systems and mitosis. In addition, PEMFs
induce some changes in membrane transport capacity
through impacting the osmotic potential, ionic valves and
leading to reduction in cellular stress factors, increase in
the rate of DNA transcription, and modulation of immune
PEMFs have also an immunomodulatory effect, as supported
by in vivo evidence showing an increase in tumor
necrosis factor alpha levels that induce an anti-tumoral
response, leading to the activation of a proapoptotic pathway
induced by caspase-8 interaction with Fas-associated
death domain, in the spleen of the murine melanoma
mouse model after a 16-day therapy . Changes in
blood pressure, skin electrical resistance, and pulse amplitude
in 163 oncology patients exposed to tumor-specific
PEMF frequencies have also been reported suggesting that
PEMF therapy does not only target neoplastic cells, but
may also have systemic effects . However, long-term
PEMF treatment in HCC patients is not toxic, confirming
the safety of PEMF therapy that employs 100,000 times
lower frequencies if compared with radiofrequency ablation
that is also employed for treatment of HCC .
In conclusion, two clinical studies have used
PEMF therapy for cancer treatment. These studies show
that PEMF therapy is safe and promising compared to
other available cancer therapies. In the future, PEMFs
could be used not only as primary therapy but also in
combination with other common antineoplastic therapies.
Given that new portable and affordable PEMF devices
are increasingly available on the market, future controlled
clinical studies are expected to further determine the
potential of PEMF therapy in oncology
|PMF sensitized fibrosarcoma and hepatocellular carcinoma to mitomycin C||An article published in the Japanese Journal of Cancer research, investigated the effects of PMF therapy in combination with mitomycin C for the treatment of fibrosarcoma and hepatocellular carcinoma.
WKA rats were exposed to a frequency of 200Hz immediately after IV injections of mitomycin C. The survival rates of the rats were recorded. Cultured cells were also used to study the efficacy of PMF and mitomycin C, and a combination of the two.
Survival rates of the untreated rats were 0% in the non-treated group, 34% in the group treated with mitomycin C only, and 47% for the PMF only group. For the group who received a combination of PMF and mitocycin C, the survival rate was 77%. The combination increased lifespan of the PMF mitomycin C group which was significantly prolonged at 17,6%. The efficiencies of the cells in the cultures of both cell lines were also significantly suppressed in the combination therapy group when compared with those in the other single therapy groups.
This study clearly indicates the possibility that PEMF therapy could improve and enhance the efficacy of drugs like mitomycin C.
|Low frequency EMF sensitizes cisplatin-resistant ovarian adenocarcinoma
|Platinum based drugs like cisplatin often form the first line of therapy for cancers including testicular, bladder, esophageal cancer, lung cancer, mesothelioma, brain tumors, neuroblastoma ovarian and colorectal tumors but the use of cisplatin also often results in chemotherapy resistant cancers.
In the search for a way to re-sensitize cancers to cisplatin, researchers investigated the use of extra-low frequency electromagnetic field therapy on cisplatin-resistant A2780 ovarian cancer cells. Cells were exposed to 200hz at 50 Gauss.
Researchers found that EL-EMF decreased proliferation of the cells independently of cisplatin. They also saw a decreased proliferation rate of 40 % in the cisplatin only group but the cells treated with a combination of cisplatin and EL-EMF showed a 71 % decrease in viability in rats. They also saw a large increase in late apoptosis in the combination group as indicated in the graph below:
Histogram from percentage of live and dead cells from AO/PI staining for A2780 cells, data are presented as means (±SD)
The study concluded that EL-EMF therapy at 200Hz can help to sensitize cancer cells to cisplatin and improved the efficacy of cisplatin.
|Pulsed magnetic fields enhance the potency of daunorubicin in human carcinoma cell lines
|Researchers studied the effects of PMF pulses of 250Hz on multidrug resistant human carcinoma cells. They inoculated mice with a multidrug resistant form of human carcinoma. They then treated the resultant tumors with pulsed magnetic therapy only or a combination of PMF therapy and daunorubicin.
Researchers found that amongst the various groups, significant differences in the tumor volume were found between PMF + saline and PMF + daunorubicin groups at 39 days and 42 days. No mice died in the PMF alone group, and no toxicity attributable to PMF was found during the experimental period.
The results indicated that the efficacy of daunorubicin was potentiated in vitro by PMF exposure when PMF exposure occurred in the presence of the drug.
|PEMF improves the effects of doxorubicin in Osteosarcoma
|In another study, researchers studied the potential drug resistance modification effects of PEMF stimulation in multidrug resistant mouse osteosarcoma. PEMF stimulation reversed doxorubicin resistance. The concluded that PEMFs reversed the doxorubicin resistance of the MOS/ADR1 cells by inhibiting P-gp function. The results suggested that PEMFs may be useful as a local treatment for multidrug resistant osteosarcoma|
|50Hz enhances the antiproliferative effects of 5-fluorouracil in breast cancer
|Finally, researchers explored the effects of pre-exposure to 50Hz to help to reduce resistance to 5-fluorouracil to enhance efficacy of the drug. The study explored the combined effect of 50 Hz-EMFs and 5-FU in the treatment of breast cancer.
Researchers found that pre-exposure to 50 Hz-EMFs enhanced the antiproliferative effect of 5-FU in breast cancer cell line MCF-7 in a dose-dependent manner but did not affect normal human breast epithelial cell lines.
They concluded that the enhanced cytotoxic activity of 5-FU on MCF7 cells through promoting entry into the S phase of the cell cycle via exposure to 50 Hz-EMFs, may provide a novel method of cancer treatment based on the combinatorial use of 50 Hz-EMFs and chemotherapy.
For more information on cancer and drug resistance please read
For more information, research and studies on TENS PEMF therapy in the management of Cancer, please join our newsletter or check back regularly for updates.